Abstract:4600 Background: Hepatocellular carcinoma (HCC) represents the second most common cause of cancer deaths worldwide. □-fetoprotein (AFP) is the most common serological test used for screening and diagnosis of HCC. However, it is widely recognized that AFP has lower sensitivity with sub-optimal specificity. Tumor-originated circulating cell-free DNA (cfDNA) provides new opportunity for non-invasive detection of liver cancer. Methods: HCC-specific differentially methylated regions (DMRs) were identified by whole genome bisulfite sequencing (WGBS) in 44 pairs of HCC tissues and adjacent tissues. We then performed methylome profiling on cfDNA from HCC patients and healthy individuals by targeted bisulfite sequencing covering genome-wide CpG islands, shelves, and shores. We employed machine learning approaches to build diagnostic models based on cfDNA regional methylation level to classify the plasma of HCC (n = 140) from that of healthy individuals (n = 84). Further analyses were performed in the validation cohort, including 155 HCC patients, and a control group with 96 healthy individuals, 21 chronic hepatitis B infection (CHB)/liver cirrhosis (LC) patients and 34 patients with benign hepatic lesions (BHL). Area under the receiver operating characteristic curve (AUC-ROC) was used to evaluate diagnostic performance. Results: A random forest classifier achieved an AUC of 0.97 (sensitivity: 92.9%; specificity: 89.4%) with 10-fold cross-validation using a panel of 39 DMR markers. The AUC of the diagnostic panel was 0.93 (sensitivity: 81.3%; specificity: 90.7%) in validation cohort, and it performed equally well in detecting BCLC stage 0+A (AUC = 0.90; sensitivity: 74.7%) and AFP negative (AUC = 0.92; sensitivity: 79.4%) HCC, as well as differentiating HCC from CHB/LC and BHL. Based on these results, we have further developed a small targeted bisulfite sequencing panel covering 127 CpG sites for non-invasive diagnosis of HCC. The panel had similar performance in training and validation cohorts, an AUC of 0.96 (sensitivity: 90.7%, specificity: 88.2%) in the training set, and 0.91 (sensitivity: 80.0%, specificity: 88.7%) in the validation set. Conclusions: Our diagnostic panel with 39 DMR markers showed high sensitivity and specificity in HCC diagnosis as well as surveillance in high-risk populations for developing HCC. More importantly, simple diagnostic model show similar diagnostic performance for early HCC diagnosis, which was easily to transfer to clinical application in the future.

Integration of Resol/block-Copolymer Carbonization and Machine Learning: A Convenient Approach for Precise Monitoring of Glycan-Associated Disorders

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Multiscale Element-Doped Nanowire Array-Coupled Machine Learning Reveals Metabolic Fingerprints of Nonreversible Liver Diseases.

Novel Three-Dimensional Hierarchical Porous Carbon Probe for the Discovery of N-Glycan Biomarkers and Early Hepatocellular Carcinoma Detection.

Machine Learning Reveals Serum Glycopatterns as Potential Biomarkers for the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD)

Screening and Diagnosis of Colorectal Cancer and Advanced Adenoma by Bionic Glycome Method and Machine Learning.

High throughput human plasma N-glycan analysis using DNA analyzer and multivariate analysis for biomarker discovery

Comparison of the methods for profiling N-glycans—hepatocellular carcinoma serum glycomics study

A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.

Multidimensional Interactive Cascading Nanochips for Detection of Multiple Liver Diseases via Precise Metabolite Profiling

Identification of Effective Diagnostic Biomarker and Immune Cell Infiltration Characteristics in Acute Liver Failure by Integrating Bioinformatics Analysis and Machine-Learning Strategies

Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS

Application of Serum N -Glycan Profiling Diagnostic Model in Evaluation of Liver Fibrosis in Patients with Hepatitis C

A Glycoform‐Resolved Dual‐Modal Ratiometric Immunoassay Improves the Diagnostic Precision for Hepatocellular Carcinoma

High-throughput site-specific N-glycoproteomics reveals glyco-signatures for liver disease diagnosis

Spatial omics-based machine learning algorithms for the early detection of hepatocellular carcinoma

AgPd NPs-based Lateral flow immunoassay for simultaneous detection of glycocholic acid and alpha-fetoprotein

N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: A large-scale multicenter study

Genome-wide Plasma Cell-Free DNA Methylation Profiling to Identify High-Performing Biomarkers for Early Detection of Hepatocellular Carcinoma.

Water-stable Hydrophilic Metal Organic Framework Composite for the Recognition of N-glycopeptides During Diabetes Progression by Mass Spectrometry.

Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma